Medical Patent News

RSS

Bioniche announces issuance of new patents for MCC, Oligonucleotide technology platforms

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced the issuance of a number of patents for its proprietary Mycobacterial Cell Wall-DNA Complex (MCC) composition and its Oligonucleotide technology platform.

18 Jun 2010

Quick-Med Technologies receives Notice of Allowance for MultiStat family of compounds

Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for intellectual property that extends the current patent coverage for the Company's MultiStat family of compounds. The forthcoming patent is part of a portfolio that Quick-Med has licensed from the University of Michigan.

18 Jun 2010

U.S. District Court pre-trial ruling favors SPI Pharma in Roquette Freres patent dispute

On Friday June 11th, Chief Judge Gregory Sleet of the United States District Court for the District of Delaware issued an important pre-trial ruling in the long-running patent dispute between SPI Pharma and Roquette Freres.

18 Jun 2010

Mount Sinai School of Medicine, Alnylam collaborate to develop microRNA-based attenuated influenza viruses

Mount Sinai School of Medicine has completed an exclusive option agreement with Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, for intellectual property related to RNAi applications in vaccine development. These new applications of RNAi technology define opportunities for the advancement of novel vaccines in infectious disease.

18 Jun 2010

ACT awarded patent for production processes of RPE cells from hESCs

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it has been issued U.S. Patent Number 7736896, which is broadly directed to processes developed by ACT scientists for the production of retinal pigment epithelial (RPE) cells from human embryonic stem cells (hESCs).

17 Jun 2010

USPTO issues patent covering Probuphine for opiate addiction

Titan Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued patent number 7,736,665 covering Probuphine for the treatment of opiate addiction.

16 Jun 2010

AVEO granted patents for tests to identify cancer patients likely to respond to tivozanib

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the issuance of U.S. Patent Nos. 7,615,353, which issued in November 2009, and 7,736,861, which issued yesterday.

16 Jun 2010

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Today, Bayer HealthCare Pharmaceuticals Inc. and Bayer Schering Pharma AG sued Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals LLC, and Barr Laboratories, Inc. in the Northern District of Illinois (Chicago) for false advertising and patent infringement in connection with Teva's generic oral contraceptive, Gianvi™. Teva's product is sold as a generic version of Bayer HealthCare's leading oral contraceptive YAZ®.

16 Jun 2010

Cardio-perfusion circuit patent portfolio offered for sale

ICAP Ocean Tomo, the intellectual property brokerage division of ICAP plc (IAP.L), is offering for sale a portfolio of three US issued patents relating to a condensed perfusion circuit for cardiac bypass. The technology of the portfolio should be of interest to any medical device company currently working in the cardiac surgery sector, or looking to establish a leading position in this growing field. This portfolio is a strong addition to ICAP Ocean Tomo's growing Bio/Life Sciences practice.

15 Jun 2010

USPTO issues patent covering methods for enhancing RNA silencing activity of RNAi agents

Silence Therapeutics plc announces the issuance of United States patent 7,732,593, titled Methods and Compositions For Controlling Efficacy of RNA Silencing, by the United States Patent and Trademark Office. The issued patent, which is based on the seminal research of Phillip D. Zamore, Ph.D., Howard Hughes Medical Institute Investigator, the Gretchen Stone Cook Chair of Biomedical Sciences, and Professor of Biochemistry & Molecular Pharmacology at University of Massachusetts Medical School, generally claims methods of enhancing the RNA silencing activity of RNA interference (RNAi) agents through certain structural modifications.

14 Jun 2010

Cubist to oppose Teva’s attempt to add new defense in patent infringement litigation

Cubist Pharmaceuticals, Inc. today announced that it will oppose a motion filed by the Teva defendants to amend their answer to add a new defense in the patent litigation between Cubist and Teva pending in the US District Court for the District of Delaware. A motion for leave to amend the answer is a request to be permitted to add a new allegation. The Teva defendants seek leave to amend their answer to allege that US Patent Nos. 6,468,967 and 6,852,689 are unenforceable due to inequitable conduct.

11 Jun 2010

I-Flow reaches agreement with Apex, Zone to resolve patent infringement, trade secret litigation

I-Flow Corporation, a subsidiary of Kimberly-Clark Corporation, is pleased to announce that it has reached an agreement resolving patent infringement and trade secret litigation against Apex Medical Technologies, Inc. and Zone Medical, LLC effective June 10, 2010.

11 Jun 2010

Gilead Sciences receives Paragraph IV Certification Notice Letter regarding Lupin's generic Ranexa ANDA

Gilead Sciences, Inc. today announced receipt of a Paragraph IV Certification Notice Letter advising that Lupin Limited submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Ranexa® (ranolazine extended-release tablets).

11 Jun 2010

PURE Bioscience's anhydrous SDC technology granted US patent

PURE Bioscience today announced that the United States Patent and Trademark Office issued patent number 7,732,486, which covers PURE's anhydrous silver dihydrogen citrate technology.

10 Jun 2010

Nativis awarded patents in Japan, China, India for drug signal technology

Nativis, Inc., a La Jolla, Calif.-based life science company, has been issued patents in Japan, China and India for its innovative technology that captures the unique signals of approved drugs at the atomic level and then delivers the signal in a solution to treat serious illnesses. The technology, which also has U.S., Canadian and Australian patents, promises to transform the treatment of diseases, including those for which there are no known cures, such as brain cancer.

10 Jun 2010

ADF Solutions awarded key patent for digital forensics

ADF Solutions, Inc., the leading provider of forensic triage tools for computers and peripherals, is pleased to announce that it has been granted a patent by the U.S. Patent and Trademark Office pertaining to methods of searching forensic data. The patent has critical applications for forensic triage, cyber-security, cyber-intelligence, digital forensics, and e-discovery.

10 Jun 2010

Intellect Neurosciences receives Notice of Allowance from Israeli patent office for OXIGON drug candidate

Intellect Neurosciences, Inc announced it has received a Notice of Allowance from the Israeli Patent and Trademark Office for a new patent related to the Company's clinical-stage drug candidate OX1 (OXIGON), which has disease-modifying potential for Alzheimer's and other neurodegenerative disorders.

9 Jun 2010

Endo, Penwest announce settlement of OPANA ER litigation with Impax

Endo Pharmaceuticals and Penwest Pharmaceuticals announced today that the companies have settled litigation with Impax Laboratories, Inc. regarding the production and sale of generic formulations of OPANA® ER (oxymorphone hydrochloride) Extended Release tablets.

9 Jun 2010

USTPO awards Melior Discovery Notice of Allowance for type II diabetes and obesity drug candidate

Melior Discovery, Inc. announced today the United States Patent and Trademark Office (USTPO) has awarded a Notice of Allowance for a broad patent application covering the Company's use of MLR-1023 for, among other things, the treatment of type II diabetes and obesity. The patent will cover use of MLR-1023 for the treatment of type II diabetes, obesity and metabolic syndrome, including its use in combination with other compounds and as a component in other drugs.

8 Jun 2010

U.S. Court issues claim construction order in patent infringement litigation between Cubist and Teva

Cubist Pharmaceuticals, Inc. today announced that the U.S. District Court for the District of Delaware issued a claim construction order in the litigation between Cubist and Teva.

8 Jun 2010

Medical Patent News

Bioniche announces issuance of new patents for MCC, Oligonucleotide technology platforms

Quick-Med Technologies receives Notice of Allowance for MultiStat family of compounds

U.S. District Court pre-trial ruling favors SPI Pharma in Roquette Freres patent dispute

Mount Sinai School of Medicine, Alnylam collaborate to develop microRNA-based attenuated influenza viruses

ACT awarded patent for production processes of RPE cells from hESCs

USPTO issues patent covering Probuphine for opiate addiction

AVEO granted patents for tests to identify cancer patients likely to respond to tivozanib

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Cardio-perfusion circuit patent portfolio offered for sale

USPTO issues patent covering methods for enhancing RNA silencing activity of RNAi agents

Cubist to oppose Teva’s attempt to add new defense in patent infringement litigation

I-Flow reaches agreement with Apex, Zone to resolve patent infringement, trade secret litigation

Gilead Sciences receives Paragraph IV Certification Notice Letter regarding Lupin's generic Ranexa ANDA

PURE Bioscience's anhydrous SDC technology granted US patent

Nativis awarded patents in Japan, China, India for drug signal technology

ADF Solutions awarded key patent for digital forensics

Intellect Neurosciences receives Notice of Allowance from Israeli patent office for OXIGON drug candidate

Endo, Penwest announce settlement of OPANA ER litigation with Impax

USTPO awards Melior Discovery Notice of Allowance for type II diabetes and obesity drug candidate

U.S. Court issues claim construction order in patent infringement litigation between Cubist and Teva

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Latest News